|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
5
|
Resverlogix Corp.
|
Dec 02, 2019 09:07AM
|
|
Re: David Kideckel now with AltaCorp
|
5
|
Resverlogix Corp.
|
Oct 05, 2018 09:09AM
|
|
Re: The MD@A for the period ending July 31, 2017
|
5
|
Resverlogix Corp.
|
Sep 14, 2017 11:34PM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
|
5
|
Resverlogix Corp.
|
Jul 15, 2019 03:58PM
|
|
Re: European Atherosclerosis Society 2019 meeting May 26-29
|
5
|
Resverlogix Corp.
|
May 27, 2019 03:28PM
|
|
Re: Melanotransferrin receptor vs. Transferrin Recepor
|
5
|
BIOASIS TECHNOLOGIES INC
|
Sep 04, 2018 11:50PM
|
|
Re: Top 5 things Apabetalone could correct for our health,...
|
5
|
Resverlogix Corp.
|
Nov 11, 2019 10:58AM
|
|
Keystone and Dialysis Conference
|
5
|
Resverlogix Corp.
|
Feb 01, 2017 04:36PM
|
|
Re: 3600 patient years
|
5
|
Resverlogix Corp.
|
Feb 17, 2018 02:35PM
|
|
Re: Surprising.....
|
5
|
Resverlogix Corp.
|
Oct 01, 2019 10:52AM
|
|
Re: BETonMACE details
|
5
|
Resverlogix Corp.
|
May 16, 2018 10:18PM
|
|
Re: The runway is clear....
|
5
|
Resverlogix Corp.
|
Dec 08, 2018 03:08PM
|
|
Re: Zenith Financing Update
|
5
|
Zenith Epigenetics
|
May 13, 2016 11:47AM
|
|
Re: FA expectations
|
5
|
Resverlogix Corp.
|
Sep 19, 2017 05:09PM
|
|
Re: Third Eye, AHA, US Listing
|
5
|
Resverlogix Corp.
|
Sep 11, 2019 03:26PM
|
|
Re: Sounds like great news!
|
5
|
Resverlogix Corp.
|
Feb 18, 2020 03:56PM
|
|
Re: "57% relative risk reduction of MACE in patients with diabetes mellitus (DM) and CVD..."
|
5
|
Resverlogix Corp.
|
Aug 14, 2018 09:21AM
|
|
Tick tock
|
5
|
Resverlogix Corp.
|
Dec 11, 2018 10:43AM
|
|
Re: If BP buys Apabetalone,...
|
5
|
Resverlogix Corp.
|
Nov 06, 2019 02:27PM
|
|
Re: A fair and optimistic write up on BETonMACE
|
5
|
Resverlogix Corp.
|
Nov 22, 2019 10:24AM
|
